Oculis Holding AG
NASDAQ:OCS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
CH |
|
Media Asia Group Holdings Ltd
HKEX:8075
|
HK |
|
Federal Realty Investment Trust
NYSE:FRT
|
US |
|
D
|
Dafeng Port Heshun Technology Company Ltd
HKEX:8310
|
HK |
|
A
|
Avenira Ltd
ASX:AEV
|
AU |
|
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
|
US |
|
Investment AB Latour
STO:LATO B
|
SE |
|
T
|
thyssenkrupp nucera AG & Co KgaA
XETRA:NCH2
|
DE |
|
technotrans SE
XETRA:TTR1
|
DE |
|
R
|
Revolution Co Ltd
TSE:8894
|
JP |
|
R
|
Ronesans Gayrimenkul Yatirim AS
IST:RGYAS.E
|
TR |
|
MDJM Ltd
NASDAQ:UOKA
|
UK |
|
M
|
Metalo Manufacturing Inc
CNSX:MMI
|
CA |
|
P
|
PacWest Bancorp
F:F8B
|
US |
|
22nd Century Group Inc
NASDAQ:XXII
|
US |
|
H
|
Honkarakenne Oyj
OMXH:HONBS
|
FI |
|
China Merchants Property Operation & Service Co Ltd
SZSE:001914
|
CN |
|
Estika Tata Tiara Tbk PT
IDX:BEEF
|
ID |
|
S
|
Shenzhen Jove Enterprise Ltd
SZSE:300814
|
CN |
|
Prestige Estates Projects Ltd
NSE:PRESTIGE
|
IN |
|
C
|
CWT International Ltd
HKEX:521
|
HK |
|
E
|
Euwax AG
F:EUX
|
DE |
|
Jindal Worldwide Ltd
NSE:JINDWORLD
|
IN |
|
D
|
Dragon Crown Group Holdings Ltd
HKEX:935
|
HK |
Oculis Holding AG
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
